A Phase 1 interventional study of AZD0284 oral solution 2.5 mg/mL and Placebo in Plaque Psoriasis Vulgaris, sponsored by AstraZeneca. Terminated at 4 sites in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-25.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Psoriasis by AstraZeneca — none open to participants now, none under way, none of them phase 3. Psoriasis · AstraZeneca.
Among the 11 studies in Psoriasis by AstraZeneca, this one is one of 2 that started in 2017, is one of 5 in phase 1, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 11 studies in Psoriasis by AstraZeneca is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 44 across the 9 interventional studies, 550 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Psoriasis by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated.
The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.
This is a randomised, double-blind, placebo-controlled, multi-centre, parallel group Phase 1b study, designed to evaluate the pharmacodynamic effects, clinical efficacy and safety of AZD0284 compared with placebo as measured by the relative change from baseline in Psoriasis Area Severity Index (PASI score), other disease assessments of involved body surface area (BSA), static physicians global assessment score (sPGA), pruritis and biomarkers associated with the mechanism of disease and AZD0284. Disease activity will be assessed throughout the study as will changes in skin biopsy biomarkers. The study population will be comprised of patients with moderate to severe plaque psoriasis as defined by PASI score, BSA and sPGA.
Following completion of screening assessments and meeting all eligibility criteria, patients will be randomised to receive AZD0284 or placebo for 4 weeks of treatment followed by a 4 week follow up period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for AZD0284 oral solution
Drug: Placebo
AZD0284 oral solution 2.5 mg/mL
Drug: AZD0284 oral solution 2.5 mg/mL
Drug page: AZD-0284
AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
Also known as: AZD0284
Placebo for AZD0284 oral solution, twice daily for 4 weeks
Reduction from baseline to the end of treatment, in gene expression level of IL-17A and CCL20 relative to placebo.
Reduction from baseline to the end of treatment, in gene expression level of IL-17A and CCL20 relative to placebo.
Time frame: 4 weeks
Percent improvement from baseline to the end of treatment in individual Psoriasis Area and Severity Index (PASI) compared to placebo
Change (percent improvement) in Psoriasis Area and Severity Index score(PASI) compared to placebo
Time frame: 4 weeks
Proportion of patients achieving 75 % reduction from baseline in PASI score, i.e. PASI 75, at week 4
Percent patients acheiving a 75% reduction in PASI score
Time frame: 4 weeks
Proportion of patients achieving 50 % reduction from baseline in PASI score, i.e. PASI 50, at week 4
Percent patients acheiving a 50% reduction in PASI score
Time frame: 4 weeks
Reduction in static physician's global assessment (sPGA) score from baseline at week4
The change in the Static physician's global assessment (sPGA) score will be assessed
Time frame: 4 weeks
Percent improvement from baseline in involved body surface area (BSA) at week 4
The percent change in the involved body surface area (BSA) will be assessed
Time frame: 4 weeks
Reduction in the pruritus visual analogue scale (pVAS) score from baseline, at week 4
The reduction in the pruritus visual analogue scale (pVAS) score as determined by the patient will be assessed
Time frame: 4 weeks
Cmax : maximum observed plasma concentration
Maximum observed plasma concentration (Cmax) will be assessed
Time frame: 4 weeks
tmax time to reach Cmax
The time to reach the maximum observed plasma concentration (Cmax) will be assessed
Time frame: 4 weeks
Cmin minimum observed plasma concentration
The minimum observed plasma concentration (Cmin) will be assessed
Time frame: 4 weeks
AE(s) and SAE(s)
Safety evaluation will include the assessment of adverse and serious adverse events over the course of the study
Time frame: Approximately 8 weeks throughout the study
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Apr 2018, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD-0284